Profile data is unavailable for this security.
About the company
Golden Throat Holdings Group Co Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical, healthcare food and other products. The Company has three products categories that include Golden Throat Lozenges (Over the Counter), which is designed to relieve symptoms of sore and dry throat and hoarse voice caused by acute pharyngitis, Golden Throat Series Products including Dule Lozenges and others, and other products including Yinxingye Tablet, Golden Throat Intestinal Series and others. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)1.08bn
- Net income in HKD281.99m
- Incorporated2014
- Employees860.00
- LocationGolden Throat Holdings Group Co LtdNo. 28 Fengxiang RoadLIUZHOU ChinaCHN
- Phone+86 7 722825718
- Websitehttp://www.goldenthroat.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SinoMab Bioscience Ltd | 2.18m | -214.69m | 1.22bn | 214.00 | -- | 4.11 | -- | 561.21 | -0.2061 | -0.2061 | 0.0021 | 0.2728 | 0.0023 | -- | -- | 10,133.96 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Jbm (Healthcare) Ltd | 720.54m | 163.88m | 1.30bn | 279.00 | 8.08 | 1.30 | 5.95 | 1.80 | 0.1955 | 0.1955 | 0.8564 | 1.22 | 0.5069 | 4.64 | 4.38 | 2,582,581.00 | 12.10 | 4.38 | 15.12 | 5.52 | 51.75 | 46.47 | 23.86 | 12.69 | 1.27 | 54.59 | 0.0768 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.53bn | 1.46k | 6.00 | 0.7603 | 4.82 | 0.9463 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.64bn | 1.72k | 7.49 | 0.6845 | 4.66 | 1.12 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| Cryofocus Medtech Shanghai Co Ltd | 44.64m | -114.27m | 1.66bn | 370.00 | -- | 13.12 | -- | 37.23 | -0.4779 | -0.4779 | 0.1867 | 0.5299 | 0.1881 | 0.418 | 4,369.58 | 113,882.00 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| Ascletis Pharma Inc | 10.85m | -277.97m | 1.73bn | 219.00 | -- | 0.7645 | -- | 159.19 | -0.2678 | -0.2678 | 0.0105 | 2.32 | 0.0041 | 1.34 | 3.58 | 49,547.89 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| VIVA Biotech Holdings | 2.15bn | -341.98k | 1.79bn | 2.04k | -- | 0.4416 | 7.17 | 0.8364 | -0.0054 | -0.0054 | 1.04 | 1.90 | 0.2603 | 5.26 | 5.18 | 1,033,075.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.16bn | 605.57m | 1.83bn | 1.18k | 3.03 | 0.5209 | 2.68 | 1.58 | 0.4031 | 0.4031 | 0.7723 | 2.34 | 0.2838 | 2.05 | 6.17 | 1,014,896.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| Golden Throat Holdings Group Co Ltd | 1.08bn | 281.99m | 2.31bn | 860.00 | 8.18 | 1.67 | 7.12 | 2.13 | 0.3814 | 0.3814 | 1.46 | 1.87 | 0.4994 | 3.23 | 4.07 | 1,245,268.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
| Cutia Therapeutics | 213.85m | -563.89m | 2.66bn | 360.00 | -- | 1.99 | -- | 12.42 | -1.85 | -1.85 | 0.7026 | 4.19 | 0.1206 | 2.31 | 6.93 | 717,626.40 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Golden Throat Holdings Group Co Ltd's reporting currency: Hong Kong Dollar HKD
0.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 2.97m | 0.40% |
| AXA Investment Managers UK Ltd.as of 30 Sep 2024 | 275.50k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 38.16k | 0.01% |
| DFA Australia Ltd.as of 30 Sep 2024 | 9.32k | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
